PULMONEM

ARDS Therapeutic

Late Stage, Phase 3, Clinical Asset

Corporate Presentation

Forward looking statements

This presentation contains forward-looking statements that reflect the Company's current expectations regarding future events. There's a risk that expectations, and the forward-looking statements on which they are based, will not prove to be accurate.

Readers are cautioned not to place undue reliance on forward-looking statements, as they involve risks and uncertainties that could make actual results differ materially from those projected therein and depend on a number of factors, including, but not limited to, the Company's lack of history of profitability, the availability of future financing, the Company's ability to protect its intellectual property rights and obtain patents, dependence on key personnel, the competitiveness of the marketplace, technological obsolescence, and other risks described from time to time in the Company's documents.

While the Company's acknowledges that future events and developments may cause its views to change, it undertakes no obligation to update forward-looking statements, except as required by applicable securities laws.

Shifting our focus from COVID-19 to ARDS

Pulmonem is shifting its primary focus from COVID-19 to Acute Respiratory Distress Syndrome (ARDS) in response to evolving market demands and scientific advancements. This strategic decision is driven by promising research and the substantial unmet medical need in ARDS, presenting a significant opportunity for Pulmonem to make a meaningful impact.

COVID-19 infection is only one of the multiple causes of ARDS, which is a severe condition characterized by the rapid onset of widespread inflammation in the lungs, often leading to respiratory failure. The current treatment options for ARDS are limited and primarily supportive, such as mechanical ventilation and oxygen therapy. This underscores the urgent need for innovative therapeutic interventions. The Yale medicine website reports that "In fact, in the United States, about 190,000 Americans are diagnosed with ARDS each year" and that "Even with treatment, about 25% to 40% of people with ARDS do not survive1". By pivoting towards ARDS, Pulmonem aims to leverage its expertise and resources to develop novel treatments to mitigate this critical respiratory medicine gap.

This shift aligns with Pulmonem's commitment to advancing medical science and improving patient outcomes. The company's strategic redirection towards ARDS is supported by recent scientific advancements that highlight potential pathways for effective intervention. Additionally, the high mortality rate and significant healthcare burden associated with ARDS underscore the importance of developing new therapeutic strategies.

Overall, Pulmonem's focus on ARDS reflects its dedication to addressing severe respiratory conditions through cutting-edge research and development, aiming to provide new hope for patients suffering from this debilitating syndrome.

PULMONEM

Acute Respiratory Distress Syndrome (ARDS)

- Severe infection of the lungs (e.g., pneumonia), sepsis or severe blood infections are the most common risk factor for ARDS.

- Common types of infections include:
  - Flu (influenza)
  - Respiratory syncytial virus
  - SARS-CoV-2, the virus responsible for COVID-19.

- Market size of Global ARDS Treatment:
  - estimated at $3.26B USD in 2024, and is expected to reach $4.30B USD by 2029, growing at a CAGR of 5.65% during the forecast period (2024-2029).

PULMONEM

Our Solution

- PULM-001 is an anti-inflammatory, immuno-modulator, anti-bacterial drug used to treat infectious diseases, including malaria, lupus, HIV and pneumocystis pneumonia.

PULM-001

- Pulmonem has repurposed Dapsone, a drug with a great safety profile as Acute Respiratory Distress Syndrome (ARDS) therapeutic.

- We believe that PULM-001 will improve overall survival by:
  - Reducing symptoms, complications and hospitalizations
  - Reducing ICU admissions due to acute respiratory distress (ARDS), mechanical ventilation and death

Most Importantly – IT'S AFFORDABLE

PULMONEM

Dapsone Molecule Study

Based on the respiratory failure and sudden high death rate originating from the involvement of the brainstem, especially the pre-Bötzinger complex, dapsone can be used to significantly reduce the incidence of the cases of acute respiratory distress syndrome (ARDS) and other illnesses caused by SARS-CoV-2.

Mortality rates at the ARDS onset stage were 0% with dapsone administered as a standard COVID-19 treatment and 40% without dapsone administered as a standard COVID-19 treatment, respectively.

The study has de-risked the program considerably.



PULMONEM

Experience Team of Industry Specialists

GUY CHAMBERLAND, CEO

- Ph.D. with an outstanding track record in new drug development
- Over 27 years of experience in business management, drug development and regulatory affairs with new and established pharmaceutical and natural health product companies.

DR. HOUFAR SEKHAVAT, MD

- Ophthalmologist, serial entrepreneur and innovator.
- Founder of Triple Hair Inc. (hair growth therapies) and Hexiris Pharma Inc. (treatment of glaucoma).

JEAN-PHILIPPE GRAVEL, MBA

- President & CEO, Triple Hair, Co-founder of Pulmonem Inc and Hexiris Inc. and the former CEO of a publicly listed company on the TSXV.
- A seasoned leader and entrepreneur.
- Over the last years, he built, managed and optimized corporate and scientific teams and organizations, secured necessary financing and negotiated successful partnerships and licensing agreements for four biotechnology and natural product companies, both private and public.

DR. SATISH ASOTRA, PH.D., MBA

- Chief Manufacturing Officer, Triple Hair, Pulmonem, Hexiris.
- Senior executive and strategic leader with a proven track record of driving pharmaceutical development, innovation and process improvement with 25 years of experience, including more than 12 years in product development, with Avicanna, AHI, Accucaps, Odan Laboratories and Taro Pharmaceuticals.

CHANÈLE DUMONTIER, CPA

- Chief Financial Officer, Triple Hair and Hexiris.
- With a background in finance and accounting, she possesses expertise in growth strategies, mergers and acquisitions, partnership development, strong business modeling skills, and a collaborative leadership style to drive efficient team achievement of company objectives.

Strategic Partnerships

- Retained one of the world's largest manufacturer of this drug with the capacity to produce in excess of 1 billion tablets per month
- Distribution and sale agreement signed for the US market
- Ongoing discussions with India to enroll patients in the phase 3 clinical trial
- Low cost of active pharmaceutical ingredients and product form (tablet)

PULMONEM

Patent Portfolio

Issued US patent (US113,379,39)

- Pending applications globally including in Canada, Europe, India, China, Brazil, Mexico and Australia
- International PCT submitted

- As clinical study gets underway, further patent applications required with results, modifications and improvements.
- New territory with substantial IP landscape.
- NDA to be filed under 505(b)2 will provide marketing exclusivity for 5 years.
- Corporation to seek Orphan Drug Status in Europe and USA.

PULMONEM

Pipeline of Assets

Candidate*	Indication	Status	Milestones
PULM-001 (Oral Tablet)	Laboratory confirmed corona virus disease 19 (COVID-19) with symptoms	Phase 3	1) Clinical Trial Application (CTA) to Health Canada approved, No Objection Letter (NOL) 2) REB approved by McGill University Health Centre 3) Institutional Review Board (IRB)) 4) Investigational New Drug (IND) approval 5) Issued US patent
PULM-002 Inhaled Formulations	Laboratory confirmed corona virus disease 19 (COVID-19) with symptoms in non-hospitalized patients or with hospitalized patients with severe disease	Preclinical	Initiate studies in 2024 following formulation

Pipeline of Preclinical Assets

Candidate*	Indication
PULM-003 (Intranasal)	Treatment of Allergic Rhinitis
PULM-004 (Intranasal)	Treatment of Infectious Sinusitis

Candidate*	Indication
PULM-005 (Inhaler)	Treatment of COPD (Asthma / Bronchitis) Treatment of Cystic Fybrosis
PULM-006 (Otic Formulation)	Treatment of Otitis Media

PULMONEM

Contact

HOUFAR SEKHAVAT
(506) 850-2480
houfar@hotmail.com

JEAN-PHILIPPE GRAVEL
(514) 804-4569
jpgravel@outlook.com